GigaGen Announces Issue of US Patent for Polyclonal Antibody Production

Share Article

Patent applies to production of recombinant intravenous immunoglobulin (rIVIG)

News Image
The patent is a key foothold in GigaGen's patent portfolio for the development of recombinant IVIG

GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is leveraging the invention to develop recombinant intravenous immunoglobulin (rIVIG).

GigaGen’s patent covers methods for converting nucleic acid encoding antibody fragments amplified from millions of single cells into full-length antibody expression libraries. The invention is useful for mining human or mouse antibody repertoires for monoclonal antibodies and is critical to the development of massively polyclonal antibodies, such as rIVIG. GigaGen’s rIVIG is an alternative to conventional plasma-based IVIG, a product derived from the plasma of thousands of human donors that is widely used worldwide to treat Primary Immune Deficiencies (PID) and other autoimmune and infectious diseases, generating $9B in sales annually.

“We are pleased that our inventions for drug discovery methods have been recognized with the issuance of this key intellectual property” said Dave Johnson, Ph.D., inventor of the technology and CEO of GigaGen. “This patent is a key foothold in our patent portfolio for the development of recombinant IVIG, the first recombinant polyclonal antibody therapeutic.”

About GigaGen
GigaGen is a biopharmaceutical company developing novel antibody and T cell therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of the entire human immune repertoire, capturing and genetically analyzing B and T cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. Therapies derived from natural immune repertoires mimic the body's natural immune system - they can be more effective, can have fewer side effects, and can have faster development timelines than those developed from traditional methods. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies. For more information visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jennifer Keller
GigaGen, Inc.
+1 650 799 1570
Email >
Follow >
Visit website